Activists for HIV treatment in Asia are continuing protests to prevent trade restrictions which would block access to life-saving generic HIV medicines. The European Union and India are currently negotiating a new free trade agreement, which has given rise to fears that the agreement will influence the production and export of generic medications. Thousands of demonstrators in India, Indonesia, Korea, and Malaysia amongst others, have protested against the inclusion of intellectual property rights in the EU-India Free Trade agreement.
GNP+ joins in the call to stop an new EU-India Free Trade Agreement from restricting the Indian pharmaceutical industry from producing and exporting quality generic antiretroviral medicines. This action is crucial because more than 80% of people living with HIV and 91% of children living with HIV from resource-limited settings receive life-saving generic medicines from India.
GNP+ supports advocacy and actions against the EU-India Free Trade Agreement under negotiation, and is fully behind networks of people living with HIV in India.
To read the support letter GNP+ sent to the networks of people living with HIV in India click here.
To read the GNP+ newsrelease click here: European Commission should mind the deadly impact of EU-INDIA Free Trade Agreement